NOT FOR PRODUCT PROMOTIONAL USE

JP Morgan Healthcare Conference

January 13, 2015

Giovanni Caforio Chief Operating Officer

NOT FOR PRODUCT PROMOTIONAL USE

Forward-Looking Information This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations.

In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.

This presentation also contains certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com.

2 2

NOT FOR PRODUCT PROMOTIONAL USE

Our Strategic Foundation

3

People helping patients in their fight against serious disease

I NNO VAT E I M PRO VE I NT EG RAT E

Diversified Specialty BioPharma

Best of BIOTECH

Best of PHARMA

NOT FOR PRODUCT PROMOTIONAL USE

Keys to Delivering Future Growth

Realize potential of key products

Advance a diverse and innovative pipeline

Leverage the specialty care model

Pursue disciplined capital allocation

Leverage business development

4

NOT FOR PRODUCT PROMOTIONAL USE

Our Commercial Priorities

Drive Brand Performance

Accelerate Innovation

Focus on Prioritized Markets

5

NOT FOR PRODUCT PROMOTIONAL USE

Our Key Products & Compounds

6

1 Daklinza & Sunvepra approved in Japan; Daklinza approved in Europe; 2 Opdivo approved in US, Japan

1

1

2

NOT FOR PRODUCT PROMOTIONAL USE

• Unique and differentiated profile with broad label

• Investing to drive growth and become the leading global NOAC

• Continued strong performance with accelerating trends

7

NOT FOR PRODUCT PROMOTIONAL USE

• First to offer melanoma patients the possibility of long-term survival

• Continued strong brand performance

• Recent US approval in advanced metastatic melanoma

• Additional global regulatory submissions

Realizing the Transformational Potential of I-O

8

NOT FOR PRODUCT PROMOTIONAL USE

Realizing the Transformational Potential of I-O

• Positive results from Phase 3 study in lung cancer

– CheckMate -017 stopped early for efficacy

• Broad clinical trial program ongoing for Opdivo and Yervoy

– Monotherapy and combination regimens

– Exploring more than 20 tumor types

– Registrational studies ongoing in 7 tumors

• Early stage clinical assets

– Urelumab (anti-CD137), Lirilumab (anti-KIR), anti LAG-3 Monotherapy and combination regimens in broad range of tumors

• Preclinical

– Aggressive plans for additional assets into the clinic over the next 12 – 24 months

9

NOT FOR PRODUCT PROMOTIONAL USE

Our R&D Focus

Immuno-Oncology

Immunoscience

Cardiovascular

Virology

Oncology

Small Molecules Biologics

Millamolecules Antibody Drug Conjugates

Disease Area Focus Drug Platforms

Genetically Defined Diseases

Fibrotic Diseases

10

NOT FOR PRODUCT PROMOTIONAL USE

Capital Allocation: A Balanced Approach

• Continue to be in a solid financial position:

– Strong balance sheet

– Business development remains a top priority

– Dividend commitment

6th consecutive annual increase

11

NOT FOR PRODUCT PROMOTIONAL USE

Business Development: Core to Our Strategy

Licensing Acquisition Partnerships

Strategically, Scientifically & Financially Aligned

12

NOT FOR PRODUCT PROMOTIONAL USE

Confident in Our Future

Commercial performance of key/new brands

Innovative pipeline to fuel long-term growth

Continued evolution of specialty model

Disciplined capital allocation

13

Positioned for long-term success

13

NOT FOR PRODUCT PROMOTIONAL USE

JP Morgan Healthcare Conference

January 13, 2015

Giovanni Caforio Chief Operating Officer

14